Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.60 |
| ▸ | PDE5A | O76074 | 5/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30835050 | 0.83 | PDE5A (0.70) | AMY1APDE5APDE4APDE4BPDE4C | |
| SCHEMBL28286332 | 0.83 | PDE5A (0.70) | AMY1APDE5APDE4APDE4BPDE4C | |
| SCHEMBL10745905 | 0.80 | AMY1A (0.53) | AMY1APDE5APDE4APDE4BPDE4C | |
| SCHEMBL31027930 | 0.79 | AMY1A (0.76) | AMY1APDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2096956 | 0.79 | AMY1A (0.76) | AMY1APDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12242149 | 0.77 | ABL1 (0.50) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL9009626 | 0.77 | AMY1A (0.67) | AMY1APDE5ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6520239 | 0.76 | PDE4A (0.67) | AMY1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25885094 | 0.76 | AMY1A (0.46) | AMY1APDE5APDE4APDE4BPDE4C | |
| SCHEMBL7393458 | 0.76 | AMY1A (0.71) | AMY1APDE5ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| CN-107106519-B | Therapeutic agent for human | 安克生命科学公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115569136-A | Therapeutic agent for human | 安克生命科学公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2022-03-08 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | Ions Pharmaceutical S.à r.I. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-9402834-B2 | Human therapeutic agents | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-08-02 | — | — | US | disclosed |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | HNMT, INMT, TYR | AMY1A 4678/4885PDE5A 4228/4885PDE4A 2389/4885 |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | AMY1A 4364/4885PDE5A 4668/4885PDE4A 4359/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | AMY1A 4763/4885PDE5A 4733/4885PDE4A 4292/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | AMY1A 4414/4885PDE5A 4179/4885PDE4A 3339/4885 |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885 |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885 |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | AMY1A 2904/4885PDE5A 4669/4885PDE4A 3687/4885 |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.